Protecting new and inventive innovations in this increasingly crowded area is essential, explains Ine Vanderleyden of Mewburn Ellis.
- Neurim, Flynn discover that time is not on their side 26-05-2022
- When alliances fail, is arbitration the answer? 24-02-2022
- NHS v Servier: unlawful means tort claim fails, but the long-running saga continues 17-08-2021
- UK experimental use exemptions: Part 4—the SPC manufacturing and stockpiling waiver 10-08-2021
- UK experimental use exemptions: part 1—the original 15-07-2021
Latest europe news
Large market for parallel or ‘grey’ imports of pharmaceuticals due to pricing differences in various countries | Govt consultation respondents unhappy with ‘lack of EU reciprocity’| Mewburn Ellis.